This course will with a brief overview of complying with GCP, then moving onto discussing how Covid-19 has impacted the way Clinical Trials are being managed. This included discussing challenges with patient safety and Investigational Medicinal Products (IMPs). We also looked at how the regulations from the European Medicines Agency, MHRA and the US Food and Drug Administration have been impacted by these changes.